(Q36026126)

11 August 2017

1 reference

title

Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea (English)

1 reference

11 August 2017

0 references

1 reference

1 reference

Rohini Sharma

1

1 reference

PubMed ID

15683818

11 August 2017

Peter Tobin

series ordinal

2

1 reference

PubMed ID

15683818

11 August 2017

Stephen J Clarke

series ordinal

3

1 reference

11 August 2017

1 February 2005

1 reference

Lancet Oncology Commission

11 August 2017

1 reference

11 August 2017

6

1 reference

11 August 2017

2

1 reference

11 August 2017

93-102

1 reference

Quality of life studies in chemotherapy-induced emesis.

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Emesis as a Critical Problem in Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Antiemetic study methodology: recommendations for future studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Advances in use of the 5-HT3 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

A new class of antiemetics: the NK-1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

The burdens of cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Inhibition of fluorouracil-induced stomatitis by oral cryotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

The effects of keratinocyte growth factor in preclinical models of mucositis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Modification of oral mucositis by keratinocyte growth factor: single radiation exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal Protectant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Thymidine Rescue: An Antidote for Pemetrexed-Related Toxicity in the Setting of Acute Renal Failure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver Carboxylesterase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Prevention of irinotecan plus5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Phase III Double-Blind Study of Glutamine Versus Placebo for the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Glutamine for irinotecan diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Disposition and metabolism of the flavonoid chrysin in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Prevention of chemotherapy and radiation toxicity with glutamine.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Thalidomide in cancer medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901735-3

7 January 2021

10.1016/S1470-2045(05)01735-3

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15683818